ALISO VIEJO, Calif., Nov. 1, 2010 /PRNewswire-FirstCall/ —
AVANIR Pharmaceuticals, Inc. (Nasdaq:
AVNR) today announced a management conference call to discuss
the approval of NUEDEXTA™ (dextromethorphan hydrobromide and
quinidine sulfate) by the U.S. Food and Drug Administration (FDA).
The call is scheduled for today, Monday November 1, 2010 at
5:15 a.m. Pacific time / 8:15 a.m. Eastern time.
The live call can be accessed by dialing (877) 558-3407 for
domestic callers and (706) 679-1941 for international callers.
The conference ID number is 22130601. A webcast of the
live call can be accessed by visiting AVANIR’s corporate website at
www.avanir.com. To view the
live webcast, please go to AVANIR’s website prior to the start of
the call to register, download, and install the necessary
software.
An archived copy of the webcast will be available on AVANIR’s
website for 30 days, and a telephone replay will be available
through November 6, 2010, by dialing (800) 642-1687 (domestic) or
(706) 645-9291 (international) and entering the conference ID
number 22130601.
About NUEDEXTA
NUEDEXTA™ is the first and only FDA-approved treatment for
pseudobulbar affect (PBA). NUEDEXTA is an innovative
combination of two well-characterized components; dextromethorphan
hydrobromide (20 mg), the ingredient active in the central nervous
system, and quinidine sulfate (10 mg), a metabolic inhibitor
enabling therapeutic dextromethorphan concentrations.
NUEDEXTA acts on sigma-1 and NMDA receptors in the brain,
although the mechanism by which NUEDEXTA exerts therapeutic effects
in patients with PBA is unknown.
NUEDEXTA is indicated for the treatment of pseudobulbar affect
(PBA). PBA occurs secondary to a variety of otherwise
unrelated neurologi
‘/>”/>
SOURCE
